Company Description

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

The company’s lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.

It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs.

Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Mural Oncology plc

Country	Ireland
Founded	2013
Industry	Biotechnology
Sector	Healthcare
Employees	117
CEO	Caroline Loew

Contact Details

Address: 10 Earlsfort Terrace Dublin, D02 T380 Ireland
Phone	353 1 905 8020
Website	muraloncology.com

Stock Details

Ticker Symbol	MURA
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001971543
ISIN Number	IE000LK2BOB4
SIC Code	2834

Key Executives

Name	Position
Caroline J. Loew Ph.D.	President, Chief Executive Officer and Director
Adam D. Cutler B.A.	Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Dr. Vicki L. Goodman M.D.	Chief Medical Officer
Maiken Keson-Brookes	Chief Legal Officer
Justin Levine	Head of Human Resources and Vice President of Human Resources

Latest SEC Filings

Date	Type	Title
Nov 19, 2024	EFFECT	Notice of Effectiveness
Nov 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024	SCHEDULE 13G	Filing
Nov 14, 2024	SCHEDULE 13G/A	Filing
Nov 13, 2024	S-3	Registration statement under Securities Act of 1933
Nov 13, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report
Nov 12, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2024	144	Filing
Nov 4, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

View All SEC Filings